ResMed (RMD) Tops Q2 EPS by 5c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 10/22/2026

6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

JPMorgan Downgrades ResMed (RMD:AU) (RMD) to Underweight

January 25, 2019 7:10 AM EST

JPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Neutral to Underweight with a price target of AUD13.40.

Low notes results were boosted by a one-off benefit. Sales will likely be subdued over much of 2019 as the business cycles... More

January 25, 2019 7:01 AM EST

Goldman Sachs analyst Chris Cooper downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy to Neutral with a price target of AUD15.20 (from AUD16.70).

Cooper said shares were priced for perfection going into the 2Q print and the company delivered a meaningful 3% sales... More

January 23, 2019 8:42 AM EST

Deutsche Bank downgraded ResMed (NYSE: RMD) from Buy to Hold.

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $117.69 yesterday.

... More